2.23% -0.0026

Medicus Pharma Ltd (MDCX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Medicus Pharma Ltd Stock (MDCX) Company Profile

Medicus Pharma Ltd

Healthcare (1076)

610-540-7515

300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN

Prossima data di guadagno

Ultimi documenti SEC

MDCX's Discussions on Twitter

Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MDCX Medicus Pharma Ltd	0.1588	10.20M	0	-28.53M	-20.10M	-1.7805
LLY Lilly Eli Co	1,119.12	1.00T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	267.69	641.88B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	256.56	450.61B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	144.15	357.02B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	137.60	261.31B	54.66B	13.58B	16.05B	7.0171

Medicus Pharma Ltd Borsa (MDCX) Ultime notizie

Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari

Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd Stock (MDCX) Company Profile

Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS

Medicus Pharma Ltd Borsa (MDCX) Ultime notizie

Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news

Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news

Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz

Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India

Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative

FDA authorizes the next study of a skin cancer patch - Stock Titan

Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan

Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan

Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan

Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan

CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan

Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news

Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance

Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com

Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK

Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative

New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire

Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView

MDCX Should I Buy - Intellectia AI

Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine

Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci

MDCX Stock Price, Quote & Chart - ChartMill

Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga

Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - Kalkine Media

$Medicus Pharma (MDCX.US)$ - Moomoo

Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC - The Pharma Letter

Pfizer, Medicus ink licensing deal worth up to $1B (PFE:NYSE) - Seeking Alpha

Medicus Pharma Signs Potential $1B Deal to License Pfizer’s Cancer Drug CD228V - Minichart

Medicus Pharma (MDCX) 10K Form and Latest SEC Filings 2026 - MarketBeat

Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin - TMX Newsfile

Medicus Pharma Warrant (MDCXW) Holds Steady at $0.33 as Trading Range TightensRVOL Breakout - vinanet.vn

Medicus Pharma Ltd. Warrant (MDCXW) Holds at $0.33 as Tight Trading Range PersistsVolume Gap - siam.in

Medicus (MDCX) Update: Slides 0.15% to $0.27 in the Latest Reading; Range Check - vinanet.vn

Medicus (MDCXW) Session: Ends a Quiet Session at $0.33 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Available RecordStock News - vinanet.vn

Medicus (MDCXW) Shares: Records a Muted Move to $0.33 in the Latest Session; Price Setup: Price Remains Between $0.31 Support and $0.35 Resistance in the Current UpdateCall Spread Alert - vinanet.vn

Medicus (MDCX) Quarterly Figures: The EPS Result Is Below Expectation in the Available Record; The Market Price Advances 1.15%Earnings Call Highlights - vinanet.vn

A. G. P. Maintains Medicus Pharma(MDCX.US) With Buy Rating, Cuts Target Price to $0.9 - Moomoo

Medicus Pharma on Bloomberg World - Coldwater Daily Reporter

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - dailyrecord.com

Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat

symbol__ Stock Quote Price and Forecast - CNN

Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news

Medicus Pharma advances clinical programs and r... - Pluang

Medicus Pharma advances pipeline during Q2 with key milestones - Yahoo Finance

Medicus Pharma Q2 loss widens to $11.7M, misses EPS estimate - scanx.trade

Medicus Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Corsicana Daily Sun

Medicus Pharma Ltd. Q2 2026: Net loss $(11.62M), EPS $(0.21) — 10-Q Summary - TradingView

Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a MDCX